title: Rapid eradication of Helicobacter pylori infection.
abstract: OBJECTIVE
  Current Helicobacter pylori eradication therapy for peptic ulcer disease usually involves a 2-week course of either a bismuth preparation or omeprazole in combination with antibiotics. We have studied a shorter, 7-day course of treatment to assess efficacy and tolerability.
  
  
  METHODS
  Four hundred and thirty-six patients, in three non-randomized groups, received omeprazole (40 mg mane), amoxycillin (500 mg t.d.s.) and metronidazole (400 mg t.d.s.): 308 patients received the triple combination for 14 days; 80 patients were treated for 7 days; and 48 patients received omeprazole and amoxycillin for 7 days but metronidazole for only 5 days.
  
  
  RESULTS
  Helicobacter pylori was eradicated in 89.5%, 91.1% and 87.5%, respectively (98.3%, 92.9% and 100% of metronidazole-sensitive isolates and 75.6% and 88.2% of metronidazole-resistant isolates in the first two groups). Side effects were significantly more frequent in patients who received 14 days (49%) compared with 7 days of treatment (33%); only 8/308 and 1/128 patients, respectively, failed to complete the course.
  
  
  CONCLUSIONS
  On the basis of efficacy, tolerability and cost, we conclude that a 7-day course of the omeprazole (40 mg mane), amoxycillin (500 mg t.d.s.) plus metronidazole (400 mg t.d.s.) combination is effective therapy for the eradication of H. pylori.
authors.affiliation: Department of Medicine, Ipswich Hospital, UK.
authors.forename: G D
authors.initials: GD
authors.lastname: Bell
authors.forename: K U
authors.initials: KU
authors.lastname: Powell
authors.forename: S M
authors.initials: SM
authors.lastname: Burridge
authors.forename: A F
authors.initials: AF
authors.lastname: Bowden
authors.forename: W
authors.initials: W
authors.lastname: Atoyebi
authors.forename: G H
authors.initials: GH
authors.lastname: Bolton
authors.forename: P H
authors.initials: PH
authors.lastname: Jones
authors.forename: C
authors.initials: C
authors.lastname: Brown
mesh_terms: D000328:Adult; D000368:Aged; D000658:Amoxicillin / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use*; D016009:Chi-Square Distribution; D003362:Cost-Benefit Analysis; D004347:Drug Interactions; D004357:Drug Synergism; D004359:Drug Therapy, Combination; D004361:Drug Tolerance; D005260:Female; D005500:Follow-Up Studies; D016481:Helicobacter Infections / Q000188:drug therapy*; D016480:Helicobacter pylori / Q000187:drug effects*; D006801:Humans; D008297:Male; D008795:Metronidazole / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use*; D008875:Middle Aged; D009853:Omeprazole / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use*
chemical_list: D008795:Metronidazole; D000658:Amoxicillin; D009853:Omeprazole